Rabies vaccine giant AIM Vaccine announced on November 7th that the company's developed iterative high-efficacy human diploid cell rabies vaccine has submitted a clinical application to the Center for Drug Evaluation (CDE), NMPA. This means that AIM's strategic layout for the iteration and upgrading of rabies vaccines is accelerating its implementation.

 

According to the announcement, AIM's iterative high-efficacy human diploid cell rabies vaccine demonstrates the iteration and upgrading of the product in many aspects.

 

Compared with the traditional first-generation human diploid cell rabies vaccine, AIM's developed iterative high-efficacy human diploid cell rabies vaccine has taken the lead in breaking through the technical bottlenecks of low virus titer and low yield in traditional processes, optimizing and innovating in the purification process, and significantly improving both product quality and safety.

 

Compared with the traditional rabies vaccine inoculation doses, this product can be vaccinated using both the "five-dose method" and the "simplified four-dose method" as well as the "2-1-1 four-dose method," offering more flexibility and convenience.

 

There are two types of rabies vaccines, one with serum and one without serum, but so far, no serum-free rabies vaccine has been registered and launched. The mainstream Vero cell rabies vaccine and human diploid cell rabies vaccine sold on the market are both serum-containing rabies vaccines.

 

Compared with the traditional Vero cell rabies vaccine, the human diploid cell rabies vaccine uses human diploid cells instead of Vero cells, which are homologous with humans and have natural safety advantages. The human diploid cell rabies vaccine on the market is 3 to 5 times more expensive than the Vero cell rabies vaccine, offering higher product added value.

 

From the Vero cell freeze-dried human rabies vaccine, to the iterative serum-free rabies vaccine, to the iterative high-efficacy human diploid cell rabies vaccine, and then to the mRNA iterative rabies vaccine, as the world's second-largest rabies vaccine production company, AIM is accelerating the iteration and upgrading of the rabies vaccine series, leading the in-depth technical iteration and upgrading of global rabies vaccines with its leading rabies vaccine R&D and production capabilities in the industry.

 

According to a WHO survey report, rabies remains a significant public health threat in the 21st century, with a fatality rate of nearly 100% once the disease develops. The potential market consumption of rabies vaccines is large, and the market size is expected to increase to 22 billion yuan by 2030, mainly benefiting from the iteration of new processes and the increase in demand for high-end products.

 

Industry insiders analyze that developing new types of vaccine products to provide consumers rabies vaccines with safer and better protection effect is a clear clinical need. At present, AIM's Vero cell freeze-dried human rabies vaccine has achieved a 100% pass rate in the National Institutes for Food and Drug Control's batch release for seventeen consecutive years since its launch, and its market share has always been among the top in recent years. Compared with the future growth curve and the continuously rising market space, the rabies vaccine giant AIM will have ample opportunities in market competition, continuing to lead the golden track.